IVF and OHSS Prevention: How to Protect Yourself From Risk

Author : Ritu Agarwal | Published On : 16 Jun 2026

Ovarian hyperstimulation syndrome is the most clinically significant complication of IVF ovarian stimulation, and understanding it is one of the most important pieces of knowledge any IVF patient can have before beginning a cycle. Its spectrum ranges from the mild bloating and discomfort that affects a significant proportion of stimulated patients to the severe form involving massive ascites, haemoconcentration, thromboembolic risk, and respiratory compromise that represents a genuine medical emergency requiring hospitalisation.

For the couples who experience severe OHSS, it can turn what should have been the most hopeful phase of their fertility journey into a frightening medical ordeal. And crucially, the most severe cases are in the majority of cases preventable through a combination of risk identification before the cycle, careful stimulation management during it, and specific trigger and post-retrieval strategies that have been well-validated in clinical research.

Understanding who is at risk, how OHSS develops, what the warning signs at each severity level are, and what the evidence-based prevention strategies are gives patients the knowledge to advocate for themselves throughout the stimulation process and to recognise early warning signs that warrant immediate clinical contact.

How OHSS Develops

Ovarian hyperstimulation syndrome results from an exaggerated ovarian response to stimulation that produces massively elevated vascular endothelial growth factor from the stimulated follicles. VEGF is the primary mediator of OHSS, acting on blood vessel walls to dramatically increase vascular permeability, allowing fluid to leak from the intravascular compartment into the extravascular spaces of the abdomen and chest.

This fluid shift produces the characteristic features of OHSS. Ascites, the accumulation of fluid in the peritoneal cavity, causes abdominal distension and discomfort and can accumulate rapidly in severe cases to volumes of several litres. The resulting fluid loss from the vascular compartment produces haemoconcentration, with elevated haematocrit and elevated blood viscosity that increases the risk of thromboembolic events. In severe cases, pleural effusions with fluid accumulating around the lungs impair respiratory function.

The timing of OHSS onset distinguishes two patterns with different clinical implications. Early OHSS, developing within the first three to five days after triggering, is driven by the exogenous trigger injection itself and resolves within one to two weeks if the cycle does not result in pregnancy. Late OHSS, developing seven to twelve days after triggering, is driven by HCG from an implanting embryo in a fresh transfer cycle and is typically more severe and more prolonged because the continuing HCG of the pregnancy perpetuates the VEGF-driven vascular permeability.

Who Is Most at Risk

Risk assessment before stimulation begins is the foundation of OHSS prevention, because the patients most likely to develop significant OHSS are identifiable before stimulation starts and their management can be adapted accordingly.

PCOS is the single strongest risk factor for OHSS. The large antral follicle pool that characterises PCOS creates the potential for massive multi-follicular stimulation responses, and the insulin-resistance-driven hormonal environment of PCOS amplifies VEGF production per follicle compared to non-PCOS ovaries.

High antral follicle count above fifteen to twenty follicles at baseline, regardless of PCOS diagnosis, identifies a large recruitable follicle pool that creates OHSS risk when exposed to standard or elevated gonadotropin doses.

High AMH above 3.5 ng/mL, as a direct marker of the antral follicle pool, correlates closely with OHSS risk and is one of the most commonly used pre-cycle risk stratification parameters.

Young age, which is associated with higher ovarian reserve and stronger ovarian response to stimulation, elevates OHSS risk particularly in patients under thirty with high AMH and AFC.

Previous OHSS in a prior IVF cycle is the most direct predictor of OHSS in subsequent cycles. A patient who developed moderate or severe OHSS previously will require proactive management in every subsequent cycle to prevent recurrence.

Prevention Strategies Before and During Stimulation

The most effective OHSS prevention approach combines conservative stimulation design for high-risk patients with dynamic monitoring and dose adjustment during the cycle.

Gonadotropin dose minimisation, using the lowest dose expected to produce an adequate response in high-risk patients rather than aiming to maximise egg numbers, is the primary prevention strategy during stimulation. For PCOS patients and other high-risk patients, starting gonadotropin doses below the standard range and adjusting upward only if the response is insufficient reduces the probability of an excessive response.

The antagonist protocol is preferred over the long agonist protocol for high-risk patients because it preserves the option of agonist triggering as the most effective individual OHSS prevention strategy, as described below.

Mid-cycle dose reduction, sometimes called coasting, involves reducing or temporarily stopping gonadotropin injections when estradiol rises rapidly and follicle numbers exceed the planned threshold. This allows the lead follicles to continue maturing toward trigger criteria while reducing the stimulation of smaller follicles that would otherwise continue growing and contributing to post-retrieval OHSS.

Cabergoline, a dopamine agonist, is used in some OHSS prevention protocols during the post-retrieval period to reduce VEGF receptor signalling and thereby reduce vascular permeability in high-risk patients. Several randomised trials have found reductions in OHSS incidence and severity with cabergoline administration in the week following retrieval.

The Agonist Trigger: The Most Effective Individual Prevention Strategy

In antagonist protocol cycles, replacing the standard HCG trigger with a GnRH agonist trigger is the single most effective strategy for eliminating severe OHSS in high-risk patients. As discussed in the trigger shot guide, the agonist trigger induces a natural LH surge of shorter duration than HCG, which produces complete oocyte maturation but substantially less corpus luteum stimulation in the post-retrieval period.

The reduced corpus luteum stimulation after agonist triggering dramatically reduces the VEGF production that drives early OHSS, effectively eliminating severe early OHSS in most high-risk patients who receive an agonist trigger rather than HCG. Multiple randomised trials have confirmed that agonist triggering reduces OHSS rates to near-zero in high-risk patients compared to HCG triggering.

The consequence of agonist triggering is the more severe luteal phase deficiency that requires the freeze-all strategy and deferred frozen embryo transfer as discussed in the corpus luteum guide. For high-risk patients where severe OHSS could result from fresh transfer with HCG triggering, this trade-off strongly favours the agonist trigger freeze-all approach both for safety and for the independent clinical benefits of frozen transfer in appropriately prepared cycles.

Recognising OHSS Symptoms and When to Seek Help

Despite the best prevention strategies, OHSS can still develop in susceptible patients, and recognising its symptoms early allows timely clinical assessment and management before the condition progresses to more severe stages.

Mild OHSS symptoms, including abdominal bloating, mild pelvic discomfort, nausea, and a two to three kilogram weight gain within a few days of retrieval, are common in stimulated patients and typically managed with hydration, rest, and paracetamol.

Moderate OHSS symptoms, including more significant abdominal distension, daily weight gain exceeding one kilogram, decreased urine output, and persistent nausea or vomiting, warrant prompt clinical assessment. Ultrasound confirming significant ascites and blood tests showing haemoconcentration confirm moderate OHSS and guide management decisions.

Severe OHSS symptoms requiring immediate emergency assessment include rapid and marked abdominal distension, difficulty breathing particularly when lying flat, severe pain, very reduced urine output, dizziness, and rapid heart rate. These symptoms indicate significant haemoconcentration and ascites that require hospitalisation and active medical management.

Any patient who has undergone IVF stimulation should have clear written guidance from their clinical team about OHSS symptoms and specific instructions about when to contact the clinic and when to attend emergency services, including out-of-hours contact information that is accessible before symptoms arise.

Connecting with an experienced Best IVF Center in Sikar that conducts thorough OHSS risk assessment before stimulation, designs conservative and responsive protocols for high-risk patients, uses agonist triggering and freeze-all strategies proactively for patients at elevated risk, provides clear patient education about OHSS symptoms and reporting, and maintains accessible clinical contact throughout the stimulation and post-retrieval period ensures that OHSS risk is managed with the clinical vigilance and proactive prevention strategy that this potentially serious complication demands.

Final Thoughts

OHSS is largely preventable. The patients at highest risk are identifiable before stimulation begins. The prevention strategies are well-validated and accessible. The trigger approaches that most effectively eliminate severe OHSS are available in standard clinical practice. And the symptom recognition that allows early intervention is straightforward when patients are given the clear, specific information they need before their cycle begins.

Know your risk profile. Understand the prevention strategies being applied to your cycle. Know the symptoms that require immediate clinical contact. And ensure that you have the emergency contact information you need before you need it.

For expert OHSS risk management with proactive prevention strategies, conservative protocol design for high-risk patients, and accessible clinical support throughout the most vulnerable phases of your IVF cycle, a trusted ivf clinic in jaipur with specific expertise in OHSS prevention and a genuine commitment to patient safety at every stage of treatment gives your cycle the most comprehensively protected stimulation management available.

Disclaimer: This article is intended for informational purposes only and does not constitute medical advice. If you experience severe abdominal pain, difficulty breathing, or rapid weight gain following IVF stimulation, seek emergency medical attention immediately. Please consult a qualified fertility specialist for guidance tailored to your individual health and treatment needs.